Bavarian will use own money to start RSV trials, but is still seeking a partner

After several discussions with the FDA, Bavarian Nordic has finally finished designing the study of its RSV vaccine and will start a 12,000 person phase III study in 2021.
Photo: PR / Bavarian Nordic
Photo: PR / Bavarian Nordic

As the end of the year approaches, Bavarian Nordic has started to look towards 2020, and has revealed two central points of next year's work: the purchase of two new vaccines from Glaxosmithkline and a timeline for the company's large phase III test of a vaccine against airway virus RSV.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading